APA (7th ed.) Citation

Taskinen, M., Björnson, E., Andersson, L., Kahri, J., Porthan, K., Matikainen, N., . . . Borén, J. (2020). Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects. Journal of clinical lipidology, 14(1), 77-87. https://doi.org/10.1016/j.jacl.2019.12.003

Chicago Style (17th ed.) Citation

Taskinen, Marja-Riitta, et al. "Impact of Proprotein Convertase Subtilisin/kexin Type 9 Inhibition with Evolocumab on the Postprandial Responses of Triglyceride-rich Lipoproteins in Type II Diabetic Subjects." Journal of Clinical Lipidology 14, no. 1 (2020): 77-87. https://doi.org/10.1016/j.jacl.2019.12.003.

MLA (9th ed.) Citation

Taskinen, Marja-Riitta, et al. "Impact of Proprotein Convertase Subtilisin/kexin Type 9 Inhibition with Evolocumab on the Postprandial Responses of Triglyceride-rich Lipoproteins in Type II Diabetic Subjects." Journal of Clinical Lipidology, vol. 14, no. 1, 2020, pp. 77-87, https://doi.org/10.1016/j.jacl.2019.12.003.